Acquires 51% in Matrix Labs Diagnocare and Matrix Labs via share swap

Acquisition announcedStrategic Transactions View source PDF Explain this filing

ONEGLOBAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.9%Reaction day

₹527.15

prior close

₹547.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+2.3% vs market

Healthcare Service Provider peers, median of 28sector-0.4%+3.3% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 3.3 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.9+0.7+2.3-0.4+3.3

Next day

-0.4+1.1-1.5-0.5+0.1

+0.9+1.6-0.7-0.4+1.3

+2.6+1.5+1.2-0.7+3.3

+3.4+1.3+2.1-1.1+4.5

+2.8+1.4+1.4-1.0+3.8

-1.1-2.1+1.0-1.8+0.7

15d

+3.6-0.9+4.5-3.3+6.8

+4.1-1.4+5.5-5.7+9.8

-16.5-5.5-11.0-6.6-9.9

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 28Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

One Global Service Provider board approved acquiring 51% stake each in Matrix Labs Diagnocare (FY25 turnover Rs.171.30 Cr, IVD and diagnostics) and Matrix Labs (FY25 turnover Rs.8.92 Cr, medical equipment and IVD) through a share swap. Will issue 7,15,040 equity shares at Rs.553 each (total about Rs.39.54 Cr including premium) to the sellers. Also raised authorised capital from Rs.25.05 Cr to Rs.50 Cr, appointed new auditors, and called AGM on 29 Sept 2026.

Likely market impact

Diversifies into diagnostics and IVD via share-swap acquisitions. Existing holders face dilution; sellers get about 3.5% combined stake post issue.